The Russian pharmaceutical market grew by 10% in value terms to 2.85 trillion roubles ($85 billion) in 2024, which was mainly ...

Cambridge, USA-based Merida Bioscienes, a biotechnology company pioneering a new class of precision therapeutics designed to ...

The European Commission (EC) has granted marketing authorization to Rinvoq (upadacitinib; 15mg, once daily), from US pharma ...

US biotech Annovis Bio has reported encouraging findings for its experimental therapy buntanetap in a subgroup of patients ...

US biotech Cartesian Therapeutics has reported that patients with generalized myasthenia gravis (gMG) continued to experience ...

US pharma major Bristol Myers Squibb has received full approval from the US Food and Drug Administration for the use of ...

Swiss biopharma Idorsia (SIX: IDIA) has received approval from the US Food and Drug Administration for an updated label on ...

US clinical-stage rare diseases focused Rallybio Corporation (Nasdaq: RLYB) says it will discontinue the development of its ...

Licensing agreements for Chinese drug candidates hit a record high in 2024, with large pharma in-licensing 28% of innovator drugs from Chinese biopharma companies.

A federal commission has urged the US government to invest $15 billion to protect the country’s leadership in biotechnology and prevent China from outpacing American innovation in the field. The ...

Shares of USA and UK-based KalVista Pharmaceuticals (Nasdaq: KALV) fell 4% to $11.04 yesterday, despite the company revealing it has signed a licensing deal for the commercialization rights in Japan ...

For more than four decades since the passage of the Hatch-Waxman Act, the US generic drug market has provided patients with ...